Once a new drug is discovered, there is a specific series of steps it must go through to acquire FDA approval. Before any applications are sent to the
|
|
- Corey Hutchinson
- 1 years ago
- Views:
Transcription
1 Research Primer: Introduction to the FDA Drug Approval Process and Off Label Use BRITTANY LA COUTURE OCTOBER 22, 2015 Introduction The United States is home to the majority of the world s new drug developers. With this rapidly expanding industry constantly offering Americans new health care treatments, Congress passed legislation at the turn of the 20 th century to protect citizens from quackery and ensure the safety and effectiveness of all new pharmacological treatments. Since then the Food and Drug Administration (FDA) has expanded rapidly and become a major influence on the pharmaceutical industry. The FDA Drug Approval Process Since the passage of the Food, Drug, and Cosmetics Act (FDCA), the FDA has an increasingly large role in approving products intended for human consumption. Drug approvals specifically are managed by the Center for Drug Evaluation and Research (CDER).[1] The CDER must examine and approve all applications for new molecule entities (novel drug compounds), generic drugs, and over the counter (OTC) drugs. It takes these products, on average, about 10 years from discovery to reach the market.[2]
2 Once a new drug is discovered, there is a specific series of steps it must go through to acquire FDA approval. Before any applications are sent to the FDA, the drug developer must run preclinical laboratory tests, typically using animal samples, to rule out any significant adverse effects.[3] This process takes 3 years on average. Only 1 in 1,000 drugs will make it past this stage.[4] After pre-clinical testing is finished, an Investigational New Drug (IND) application must be submitted to the FDA/CDER explaining the results of previous trials, how new studies will be conducted, how volunteer subjects will be chosen, the chemical structure of the new drug, how it is believed to work within human biochemistry, how it is manufactured, and any known or anticipated side effects.[5] If this application is not rejected within 30 days, it is considered approved. If approved, any clinical trials that are carried out must first be submitted to and approved by an Institutional Review Board (IRB) a group of scientists, academics, and subject matter experts approved by the Department of Health and Human Services (HHS) who approve and oversee experiments done on human subjects to ensure they are performed ethically.[6] Phase I clinical trials involve a small sample group of typically healthy volunteers. The purpose is to determine safe dosages, absorption rates, duration of the drug s effects, and any side effects. This stage typically takes about 1 year.[7] If Phase I trials show the drug to be relatively safe, Phase II trials begin. These involve patients and controlled studies to test minimum and maximum dosages and their effectiveness. This stage takes an additional 2 years.[8] The final stage of pre-market testing, Phase III, is a randomized, controlled study of 1,000-3,000 patients testing safety and effectiveness of the drug. This process takes approximately 3 years.[9]
3 Once clinical testing has finished, the drug developer must submit a New Drug Application (NDA) including all relevant data and information about the drug these applications often reach 100,000 pages. Approval or denial of these applications currently takes an average of 12 months. An NDA may be denied with explanation, approved outright, or approved on the condition that the manufacturer makes minor changes, such as labeling adjustments.[10] All drugs with NDAs that make it to market are subject to Phase IV, or post-marketing studies, to track the voluntary reporting of adverse side effects. Less than 3 percent of approved drugs are ever recalled based on Phase IV reporting.[11] Speeding Up the Process Speeding up the process of drug approvals has been a major concern for pharmaceutical companies and patient advocacy groups, particularly since the beginning of the AIDS epidemic in the 1980 s. Since then, several approaches to fast-tracking access to new drugs have emerged. In 1992, Congress passed the Prescription Drug User Fee Act (PDUFA), which requires drug companies submitting new drugs (and biologics) for FDA approval to pay a fee to support the CDER specifically; providing additional resources to facilitate faster drug approval.[12] Fees are also applied to up to 2 years of post-marketing studies of approved drugs to aid in quality control. PDUFA has been widely considered a success. As a compromise between companies paying the fees and the FDA, the CDER has used PDUFA funds to decrease the average approval time of NDAs from 30 months to 12 months. Since PDUFAs reauthorization in 2012, CDER has a new goal to lower the average approval time to 10 months for a standard NDA.[13]
4 There is another PDUFA-related drug approval fast track for priority drugs that treat orphan diseases, rapidly spreading diseases with no other effective treatment, chronic or widespread illnesses with no more effective treatment alternative, and qualified antibiotics.[14] Fast-track approval provides drug companies with the opportunity for more frequent communication with the FDA regarding trial design and data collection, priority review, and rolling submission of NDA materials as they become available. Under PDUFA, priority review drugs typically receive a decision from CDER within 6 months of submission.[15] Compassionate Use programs (also known as Right to Try) occasionally allow terminally ill individuals to try an experimental drug that is still going through clinical trials if the drug has been through Phase I and is not considered dangerous. Post Approval Use of Drugs Once a drug is approved by the FDA for any indication, its prescription and use is then left to the discretion of health care providers medical and ethical judgments. Off-label drug use is common and includes any use that is different from the intended and labeled indication, dose, mode of administration, patient age or gender, or duration of use.[16] Although up to 70 percent of off-label drug use lacks scientific backing,[17] it is still incredibly prevalent, and in some cases an off-label use may even become the primary reason a drug is prescribed.[18] For example, pediatric antipsychotic drugs are prescribed off-label over 77 percent of the time.[19] Off-label use is especially common among specialties where patients are rare or unable to give consent, therefore making it difficult to secure a large enough volunteer base to run clinical trials. For example, oncology, pediatrics, geriatrics, and obstetrics all rely heavily on off-label drug uses.[20] At first, drug manufacturers were prohibited from promoting a drug s off-label uses by the FDA. However, through the FDCA Congress has allowed drug companies to distribute enduring materials such as peer-reviewed journals which discuss off-label use under certain conditions including a promise to seek FDA approval.[21] Economic factors may discourage drug companies from seeking FDA approval. In many instances the patient population for off-label use is too small to produce statistically
5 significant results, or to justify their expense for a drug whose exclusivity period is already running. To address this, Congress has granted an extension of exclusivity where a new use is approved, but this is not guaranteed to recover trial costs, nor is the new approval itself guaranteed.[22] In the 1990 s, federal courts further expanded drug manufacturers interests in off-label uses by holding that promoting off-label uses is a constitutionally protected right, but that the company s financial interest and lack of FDA approval must be disclosed.[23] Subsequent FDA guidance has attempted to better delineate the extent to which knowledge of off-label drug use may be promoted. That guidance, though on questionable constitutional ground, has not yet been challenged in the courts. [1]
Goals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe
Drug Development & the FDA Pharmacy 309 Tom Hazlet, Pharm.D., Dr.P.H. 616-2732 thazlet@u... Goals & Objectives Be able to describe the major regulatory events in the drug development process the concepts
February 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
Overview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
FROM MOLECULES TO MEDICINE: HOW ARE NEW DRUGS & THERAPIES DEVELOPED?
FROM MOLECULES TO MEDICINE: HOW ARE NEW DRUGS & THERAPIES DEVELOPED? FROM MOLECULES TO MEDICINE: HOW ARE NEW DRUGS & THERAPIES DEVELOPED? Introduction This Global Genes Toolkit will provide you with an
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
Drug Development Process
Drug Development Process Original Arthur: Addie D. Anderson CRB Consulting Engineers, Inc. Overview Important milestones establishing our current system of regulations Step-by-step overview of the drug
CenterWatch. volunteering. clinical trial. for a. www.centerwatch.com
volunteering for a clinical trial www.centerwatch.com :: about this pamphlet This pamphlet provides an overview of the clinical trials process and answers frequently asked questions that many potential
Not All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
The Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
From the Text. Definitions. Definitions. Definitions. Definitions. RSPT 2217 Basic Concepts & Principles. RSPT 2217-01 Basic Concepts
RSPT 2217 & Principles Gardenhire Chapter 1; p. 1-10 From the Text Key Terms and page 2 Orphan Drugs Table 1-1; page 6 Abbreviations Table 1-2; page 8 Aerosolized Agents Table 1-3; page 9 Drug: Pharmacology:
CTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
FDA Fast Track and Priority Review Programs
Order Code RS22814 February 21, 2008 FDA Fast Track and Priority Review Programs Summary Susan Thaul Specialist in Drug Safety and Effectiveness Domestic Social Policy Division By statutory requirements
Why Are Drugs So Expensive? Learning About the Drug Development Process
Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal
Career Opportunities at FDA From a regulatory scientist perspective. Ke Zhang, Ph.D. U.S. Food and Drug Administration Silver Spring, MD
Career Opportunities at FDA From a regulatory scientist perspective Ke Zhang, Ph.D. U.S. Food and Drug Administration Silver Spring, MD Disclaimers 1. The views expressed in this presentation are those
Guidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center
Glossary of Clinical Trial Terms
Glossary of Clinical Trial Terms ADVERSE REACTION: (Adverse Event): Also known as side effects, adverse reactions include any undesired actions or effects of the experimental drug or treatment. Experimental
GAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts
GAO United States Government Accountability Office Report to Congressional Requesters November 2006 NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering
From The Lab To Your Medicine Cabinet:
From The Lab To Your Medicine Cabinet: A Pharmaceutical Drug s Journey Presented by: Dr. Steven Hansel Sr. Director; Pfizer Moderated by: Sam Gilchrist Ph.D. Candidate; UBC The Drug Development Process
POLICY AND PROCEDURES OFFICE OF NEW DRUGS. NDAs and BLAs: Communication to Applicants of Planned Review Timelines.
CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 6010.8 Rev. 1 POLICY AND PROCEDURES OFFICE OF NEW DRUGS NDAs and BLAs: Communication to Applicants of Planned Review Timelines Table of Contents PURPOSE...1
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases Andrew E. Mulberg, MD, FAAP Division Deputy Director OND/ODE3/DGIEP FDA Partnership is the Key Coming together is a beginning;
Regulatory Science and Translational Research Clinical Trials for Medical Devices What do you need to know?
Regulatory Science and Translational Research Clinical Trials for Medical Devices What do you need to know? Lynn M. Rose, PhD Research Associate Professor, Pediatrics Institute of Translational Health
Clinical Research Workshop
Clinical Research Workshop Introduction In these activities, pupils learn about how new medicines are developed from the initial idea, through the science that turns them into treatments, to the clinical
Ethical Issues Surrounding the Conduct of Pediatric Clinical Studies
Ethical Issues Surrounding the Conduct of Pediatric Clinical Studies Karsten A. Holm Saint Joseph s University Graduate Ethics Paper Competition, Fall 2013 (Word Count 3000) 1 Introduction The ethical
Guideline for Industry
Guideline for Industry The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Longterm Treatment of Non-Life- Threatening Conditions ICH-E1A March 1995 GUIDELINE FOR INDUSTRY
Postmarket Surveillance -Adverse Event Reporting in the Office of Generic Drugs
Postmarket Surveillance -Adverse Event Reporting in the Office of Generic Drugs Integration Communication Collaboration John R Peters, MD Director, Division of Clinical Review Office of Generic Drugs 1
Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions
Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions U.S. Department of Health and Human Services Food and Drug Administration
Challenges in the Regulation of Pediatric Clinical Trials
Challenges in the Regulation of Pediatric Clinical Trials Wilson W. Bryan, M.D. FDA / CBER / OCTGT wilson.bryan@fda.hhs.gov National Institutes of Health Recombinant DNA Advisory Committee (RAC) Meeting
21st Century Cures Act: Key Provisions Related to Medical Devices
21st Century Cures Act: Key Provisions Related to Medical Devices July 30, 2015 Food & Drug The 21st Century Cures Act ( the Act or HR 6 ) was passed by the House of Representatives on July 10, 2015, by
The 505(b)(2) Drug Development Pathway:
The 505(b)(2) Drug Development Pathway: When and How to Take Advantage of a Unique American Regulatory Pathway By Mukesh Kumar, PhD, RAC and Hemant Jethwani, MS The 505(b)(2) regulation offers a less expensive
Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations
Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations DRAFT GUIDANCE This guidance document is being distributed
The Product Review Life Cycle A Brief Overview
Stat & Quant Mthds Pharm Reg (Spring 2, 2014) Lecture 2,Week 1 1 The review process developed over a 40 year period and has been influenced by 5 Prescription User Fee Act renewals Time frames for review
Waiver to Allow Participation in a Food and Drug Administration Advisory Committee
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:
Biostatistics in Medical Product Regulation: Introduction. Simon Day, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
Guidance for Industry
Guidance for Industry Codevelopment of Two or More New Investigational Drugs for Use in Combination U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Regulatory Strategy 101
Regulatory Strategy 101 By Meredith Brown-Tuttle, RAC What is regulatory strategy? As a regulatory associate you hear the word strategy bandied about without any real definition. You know that is what
Cancer Clinical Trials: In-Depth Information
Cancer Clinical Trials: In-Depth Information The Drug Development and Approval Process 1. Early research and preclinical testing 2. IND application filed with FDA 3. Clinical trials (phases 1, 2, and 3)
Guidance for Industry Classifying Resubmissions in Response to Action Letters
Guidance for Industry Classifying Resubmissions in Response to Action Letters U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
POLICY AND PROCEDURES OFFICE OF PHARMACEUTICAL SCIENCE
POLICY AND PROCEDURES OFFICE OF PHARMACEUTICAL SCIENCE CLARIFICATION TELECONFERENCES BETWEEN SPONSORS, APPLICANTS, OR MASTER FILE HOLDERS AND THE ONDQA REVIEW TEAM Table of Contents PURPOSE...1 BACKGROUND...2
Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA
Medpace Discovery Series presents Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA DR. JIM WEI: Today my topic is going to be Proof-of-Concept Studies and FDA End of Phase 2a Meetings
Page 191 TITLE 21 FOOD AND DRUGS 355 1
Page 191 TITLE 21 FOOD AND DRUGS 355 1 APPEALS TAKEN PRIOR TO OCTOBER 10, 1962 Section 104(d)(3) of Pub. L. 87 781 made amendments to subsec. (h) of this section inapplicable to any appeal taken prior
Medicare Appeals: Part D Drug Denials. December 16, 2014
Medicare Appeals: Part D Drug Denials December 16, 2014 2013 Appeals Statistics by Type 23,716 Part D Reconsideration Appeals* Appeals Type Percentage of Total Appeals Appeals Per Million Medicare Beneficiaries
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
A Participant s. Guide. to Mental Health Clinical Research
A Participant s Guide to Mental Health Clinical Research Contents Purpose of this document... 1 What is clinical research?... 2 Why do people choose to participate in research?... 3 What are the different
Overview of Drug Development
Overview of Drug Development Namrata Bahadur Head of Clinical Development & Medical Affairs Emerging Growth Markets 17 th 21 st March, Bangkok 2008 Novartis The information within this presentation is
eskbook Emerging Life Sciences Companies second edition Chapter 30 Issues That Must Be Addressed in a Life Sciences M&A
eskbook Emerging Life Sciences Companies second edition Chapter 30 Issues That Must Be Addressed in a Life Sciences M&A Chapter 30 ISSUES THAT MUST BE ADDRESSED IN A LIFE SCIENCES M&A As demonstrated in
Pharmaceutical development is an expensive, time
Exclusivity Strategies in the United States and European Union by Carolyne Hathaway, John Manthei and Cassie Scherer Pharmaceutical development is an expensive, time consuming and uncertain process that
Ontario Public Drug Programs / Cancer Care Ontario Policy: Reimbursement of Publicly Funded Cancer Drugs within the Context of Clinical Trials
Ontario Public Drug Programs / Cancer Care Ontario Policy: Reimbursement of Publicly Funded Cancer Drugs within the Context of Clinical Trials Version: 2.0 Effective Date: January 29, 2016 Replaces Policy:
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER LT Andrew Fine, Pharm.D., BCPS Safety Evaluator Division of Pharmacovigilance Office of Pharmacovigilance and Epidemiology
University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
Food and Drug Administration
Center for Drug Evaluation and Research (CDER) Small Business Assistance Program The Information Source for Regulated Domestic and International Small Pharmaceutical Business CAPT Brenda Stodart, USPHS
Policy. Purpose: To mitigate the impact of disease on our membership for covered conditions.
Policy Number: Subject: PTC-8500 Prescription Drug Program Primary Authors: On File Impact: Review Dates: 9/27/05, 11/28/06, 9/27/07, 9/23/08, 9/29/09, 9/28/ 10, 9/27/11, 11/19/12, 10/21/13, 05/29/14,
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
Guidance for Industry
Guidance for Industry Fees-Exceed-the-Costs Waivers Under the Prescription Drug User Fee Act U.S. Department of Health and Human Services Office of Financial Management June 1999 User Fees Guidance for
Is it time for a new drug development paradigm?
Is it time for a new drug development paradigm? Robert McDonough, M.D. Senior Director, Clinical Policy Research and Development 1 The Aetna Way Our Cause To make quality health care more affordable and
Pre-market Information - Class III and IV
Pre-market Information - Class III and IV Life Sciences Council British Columbia NRC Industry Research Assistance Program Vancouver, October 29, 2007 Mary-Jane Bell, Ph.D. Medical Devices Bureau (MDB)
Pharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
Overview of FDA Compliance for Medical Devices
Glisland Training Series: Overview of FDA Compliance for Medical Devices Glisland, Inc. San Jose, California, USA http://www.glisland.com Description This course provides a concise overview of how FDA
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
PharmaceuticalDevelopment
PharmaceuticalDevelopment Activities & Timelines Agenda Factors driving development Types of product Timelines for development Factors affecting length of development Regulation of Pharma environment Cost
Overview of FDA Expedited Programs with a Focus on Breakthrough Therapy
Overview of FDA Expedited Programs with a Focus on Breakthrough Therapy Miranda Raggio, RN, BSN, MA CDER Breakthrough Therapy Program Manager Regulatory Affairs Team Office of New Drugs, CDER Overview
The Clinical Trial Protocol Guide. BioStrategics Consulting Ltd.
The Clinical Trial Protocol Guide 2011 BioStrategics Consulting Ltd. BioStrategics Consulting Ltd THE CLINICAL TRIAL PROTOCOL The clinical trial protocol to test one s product, to confirm or reject a specific
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications DRAFT GUIDANCE This guidance document is being distributed
Guidance for Industry
Guidance for Industry Applications Covered by Section 505(b)(2) DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
Frequently Asked Questions (FAQs) Treatment Authorization Request (TAR) Restriction on Antipsychotic Medications for the 0-17 Population
Frequently Asked Questions (FAQs) Treatment Authorization Request (TAR) Restriction on Antipsychotic Medications for the 0-17 Population Prescriber FAQs Update January 22, 2015 1. What information is needed
White Paper: Formulary Development at Express Scripts
White Paper: Formulary Development at Express Scripts Express Scripts works with health-benefit plan sponsors and individual members of health plans to provide affordable access to clinically sound, high-quality
FDA Basics For Biotech Drugs, Biologics and Devices
FDA Basics For Biotech Drugs, Biologics and Devices I. FDA Overview A. FDA has authority over products intended for the diagnosis, treatment or mitigation of human disease or intended to affect a structure
Guidance for Industry and Review Staff Target Product Profile A Strategic Development Process Tool
Guidance for Industry and Review Staff Product Profile A Strategic Development Process Tool DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
A Middle Class in the United States? Behind the Counter (BTC) Drugs. Frederick H. Branding, R.Ph., J.D. Rahul Narula
A Middle Class in the United States? Behind the Counter (BTC) Drugs Frederick H. Branding, R.Ph., J.D. Rahul Narula FDA s Regulation of Drugs Federal Food, Drug and Cosmetic Act (FDCA) passed by Congress
Adverse Event Reporting and Social Media
Adverse Event Reporting and Social Media Anne V. Maher Kleinfeld, Kaplan and Becker Social Media Regulatory Affairs Summit The National Press Club Washington, DC June 24-25, 2015 Topics FDA regulatory
Chapter 8 WHAT THE STATUTE AND REGULATIONS SAY. Combination Products. Key Points
Chapter 8 Combination Products Suzanne O Shea, Baker & Daniels, LLP, Indianapolis, IN Key Points A combination product comprises two or more different types of regulated components. It can be a drug/device,
Josephine Silvestre, RN, MSN The University of Chicago Medical Center. October 13, 2007
Josephine Silvestre, RN, MSN The University of Chicago Medical Center October 13, 2007 A study in which people participate as volunteers. A clinical trial is conducted to develop potential new treatments
Comparison of Clinical Trials Registry Legislation in the Senate and House Prepared by Tannaz Rasouli, AAMC Office of Governmental Relations
Comparison of Clinical Trials Registry Legislation in the Senate and House Prepared by Tannaz Rasouli, AAMC Office of Governmental Relations Clinical Trials Registry S. 1082 (Title II, Subtitle C) H.R.
Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation
Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation Leslie M. Tector Quarles & Brady LLP September 30, 2014 Objectives Which federal
What Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
EXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND
EXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND I. INTRODUCTION: Scope. To the extent of any conflict between the Agreement and this State
BIOTECHNOLOGY OPERATIONS
BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press
CLINICAL CLINICAL TRIALS. How Clinical Trials Work for Children
CLINICAL CLINICAL TRIALS How Clinical Trials Work for Children Today, there are only a handful of drugs approved by the U.S. Food and Drug Administration (FDA) to treat hepatitis B, C or D in adults. There
Expanded Access Programs. Richard Klein Office of Special Health issues Food and Drug Administration
Expanded Access Programs Richard Klein Office of Special Health issues Food and Drug Administration Expanded Access Programs (EAPs) What is expanded access? History Legislative background General principles
Guidance for Industry
Guidance for Industry Formal Dispute Resolution: Appeals Above the Division Level Additional copies of this Guidance are available from: Office of Training and Communications Division of Communications
ORACLE CONSULTING GROUP
ORACLE CONSULTING GROUP An Official United States Agent Firm for Foreign Establishments CONSULTING MEMORANDUM: DEALING WITH A MEDICAL DEVICE IN THE U.S. 5398 Golder Ranch Rd., Ste. 1 Tucson, Arizona 85739
CLINICAL TRIALS WITH MEDICINES IN EUROPE
CLINICAL TRIALS WITH MEDICINES IN EUROPE REGULATORY FRAMEWORK FOR CLINICAL TRIALS WITH MEDICINES IN EUROPE The pharmaceutical industry is the most highly regulated sector in Europe. The Commission has
Clinical Trials at PMH
Clinical Trials at PMH What You Need To Know UHN Patient Education Improving Health Through Education A Guide for Patients, Their Families and Friends in the PMH Cancer Program This information is to be
Waiver to Allow Participation in a Food and Drug Administration Advisory Committee
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:
Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
ORPHAN DRUG. ORPHAN DRUG & RARE DISEASE DEVELOPMENT: Understanding the U.S. and European Regulatory Landscape & RARE DISEASE DEVELOPMENT
: Abstract Today, more than ever, researchers are focused on providing care for the approximately 7,000 rare diseases that may have been overlooked in the past due to the challenges of conducting clinical
CHALLENGES TO FDA S ABILITY TO MONITOR AND INSPECT FOREIGN CLINICAL TRIALS
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL CHALLENGES TO FDA S ABILITY TO MONITOR AND INSPECT FOREIGN CLINICAL TRIALS Daniel R. Levinson Inspector General June 2010 I N T R O D
Importing pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
Roles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
Course Curriculum for Master Degree in Clinical Pharmacy
Course Curriculum for Master Degree in Clinical Pharmacy The Master Degree in Clinical Pharmacy is awarded by the Faculty of Graduate studies at Jordan University of Science and Technology (JUST) upon
They try to discover what kinds of cells the BNV infects, how it kills those cells, and what happens to the surrounding cells.
A Vaccine s Journey 2 A Journey From the time an idea blooms in someone s mind, to the time a nurse says give me your arm, the development of a vaccine takes10 or more years. The stages of development
Guidance for Clinical Investigators, Sponsors, and IRBs
Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center
RULES GEORGIA COMPOSITE MEDICAL BOARD TABLE OF CONTENTS
RULES Physician Assistant Chapter 360-5 GEORGIA COMPOSITE MEDICAL BOARD TABLE OF CONTENTS 360-5-.01 Purpose 360-5-.02 Application for Licensure as a Physician Assistant 360-5-.03 Application for Physician
Strategies to Prepare for Meetings with the FDA. Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA
Strategies to Prepare for Meetings with the FDA Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA Topics for Discussion Who Are We? How Do We Interact Internally? Why
Medicine Safety Glossary
The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive
12 April FZ. On Circulation of Medicines. Adopted by the State Duma March 24, 2010
12 April 2010 61-FZ On Circulation of Medicines Adopted by the State Duma March 24, 2010 (as amended by Federal Laws of July, 27 2010, 192-FZ; of October 11, 2010, No. 271-FZ, of November 29, No. 313-FZ,
New Drug Application (NDA) Checklist
New Drug Application (NDA) Checklist New Drug Applications (NDA) are very complex and detailed. It is difficult to know whether a company has included all of the information that is required by the applicable
Clinical Trials: Questions and Answers
Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs Charlesworth Rae, BS, PharmD, JD Investigational Drug Pharmacist July 2012 1 Outline of Presentation I. Introduction